Inventiva

10/31/2023

As draws to a close, we at Inventiva Pharma want to express our gratitude to everyone raising awareness for liver health.

At Inventiva, we are committed to raising awareness and supporting patients by developing therapies for patients suffering from / and other diseases with significant unmet medical needs.

Let's continue to prioritize our well-being and encourage those around us to do the same. To learn more about our initiatives, visit inventivapharma.com.

10/26/2023

This , let's confront a staggering reality - the global surge of NAFLD (Nonalcoholic Fatty Liver Disease). Recent data show that the prevalence of has soared to 30.05%.

The regions most impacted include Latin America and the Middle East/North Africa, with prevalence rates of 44.37% and 36.53% respectively.

These numbers are more than statistics; they represent millions of lives affected by this silent liver condition. Let's unite in raising awareness, advocating for early detection, and spreading knowledge. Together, we can combat NAFLD and pave the way to better liver health!

Learn more: https://pannash.org/nafld-global-and-regional-prevalence-incidence-and-mortality-rates/

10/17/2023

As we continue to highlight , let's delve into the strong link between (Nonalcoholic Steatohepatitis) and .

3 in 10 people with obesity also have NASH/MASH.

Excess body weight, especially abdominal obesity, can contribute to the accumulation of fat in the .

Over time, in some patients, this can lead to inflammation, scarring, and the progression to NASH/MASH.

Inventiva Pharma is committed to increase awareness and support patients by developing treatments for NASH/ .

Learn more about our initiatives: inventivapharma.com

10/10/2023

During this , we're diving into a crucial topic: the intricate link between Diabetes and Nonalcoholic Steatohepatitis (NASH).

Over 1 in 3 adults with diagnosed Type 2 Diabetes also have NASH/MASH. and / are closely related. NAFLD/NASH increase the risk of developing Type 2 Diabetes, and this promotes the progression to NASH. NASH increases the risk of cirrhosis and liver cancer.

If you have Type 2 diabetes and NASH, consider joining the NATiV3 clinical trial! Your participation in NATiV3 will help evaluate an investigational drug. Visit this website for more information: NASH-Trial.com

10/02/2023

October is Liver Awareness Month! 1 in 4 people of the world's adult population has fatty liver disease (NAFLD) which is a progressive and chronic liver disease. 1 out of 5 people with NAFLD have the most severe form of the disease, Nonalcoholic Steatohepatitis (NASH).

To date, there are still no approved therapeutics for the treatment of NASH. At Inventiva Pharma, we are committed to raising awareness and supporting patients by developing therapeutics for NASH.

Learn more about NATiV3, a Phase III clinical trial evaluating Lanifibranor in NASH: NASH-Trial.com

08/02/2023

Help make a difference in the fight against NAFLD/NASH by participating in the Fatty Liver Foundation's (FLF) annual survey: The State of NAFLD/NASH Care in America. Your valuable insights will contribute to improved education, resources, and care for adults living with NAFLD/NASH.

Last year, over 700 respondents made an impact, and this year, LiverSaver aims to reach an even larger and more diverse group. Survey available in English and Spanish. Click the links below and share your voice today!

English Survey: http://bitly.ws/PVcz
Encuesta en Español: http://bitly.ws/PVcG

Take this survey powered by surveymonkey.com. Create your own surveys for free.

06/08/2023

Today is International NASH Day and we are proud to join the Global Liver Institute, advocates and stakeholders around the globe in the fight against this silent epidemic.

To raise awareness on NASH, Inventiva’s employees are participating in a challenge to run, bike or walk a distance of 6000kms which separate our French office from our New York Office! We are proud to announce that our team completed this challenge on International NASH Day! Way to go team Inventiva, thank you for your commitment to raise awareness.

06/08/2023

On this International , Echosens is partnering with Inventiva to raise awareness about the prevalence of nonalcoholic steatohepatitis (NASH) and increase liver screening access for at-risk patients. Let's work together to improve the care of people living with NASH.

To learn more, visit: https://inventivapharma.com/news-events/

05/29/2023

This , Inventiva Pharma joins the nation in remembering and thanking the incredible individuals who made the ultimate sacrifice for our country. We're forever grateful for their bravery and dedication. Let's honor their memory and the freedom they fought for.

05/19/2023

Tomorrow, we are celebrating , and Inventiva Pharma would like to extend its deepest gratitude to all the incredible patients and dedicated clinical trial staff who play a vital role in advancing clinical research.

At Inventiva Pharma, we're committed to making a difference in the lives of patients affected by and diseases with unmet medical needs.

Learn more about NASH and our clinical programs: http://bitly.ws/EVHm

05/12/2023

Inventiva Pharma proudly joins the global community in honoring the unwavering dedication and invaluable contributions of worldwide.

Today, and every day, we recognize the extraordinary efforts of these compassionate professionals who make a difference in the lives of millions. We remain committed to supporting and collaborating with the nursing community, as together, we strive for innovative solutions that enhance the lives of individuals and communities around the world.

Share your stories of remarkable nurses who inspire you.

04/11/2023

Have you been diagnosed with NASH and liver fibrosis?
NASH does not have to be your silent partner even if there are no approved treatments.
Participating to NATiV3, a phase III clinical trial, could be an option for you.
For more information, visit: https://nash-trial.com/